Nektar Therapeutics — Quarterly Financial Statistics (NASDAQ:NKTR) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics

Quarterly Annual

Cash from operating activities 43.93 M46.19 M49.05 M45.74 M48.76 M 189.74 M Cash from investing activities 46.12 M60.21 M43.69 M49.62 M-91.73 M 61.78 M Cash from financing activities 13 K83 K7 000211 K141.68 M 141.98 M Free cash flow 43.27 M45.73 M49.05 M45.7 M48.65 M 189.13 M

Nouvelles

Oppenheimer relève l’objectif de cours de Nektar Therapeutics à 140$

Oppenheimer raises Nektar Therapeutics price target to $140

L’action Nektar Therapeutics atteint un sommet de 52 semaines à 76,3 dollars

Nektar Therapeutics stock hits 52-week high at 76.3 USD

Alerte résultats Nektar Therapeutics T4 2025 : hausse de trésorerie et expansion R&D

Earnings call transcript: Nektar Therapeutics Q4 2025 shows cash boost and R&D expansion

Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates

Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for

Wall Street Analysts Think Nektar (NKTR) Could Surge 89.8%: Read This Before Placing a Bet

Nektar Therapeutics stock hits 52-week high at 75.19 USD

Nektar Therapeutics clôture une offre publique de 460 millions de dollars